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Abstract
During transport and storage, vaccines may be exposed to temperatures outside of the range 
recommended for storage, potentially causing efficacy losses. To better understand and prevent 
such losses, Dominant Negative Inhibitor (DNI), a recombinant protein antigen for a candidate 
vaccine against anthrax, was formulated as a liquid and as a glassy lyophilized powder with the 
adjuvants aluminum hydroxide and glycopyranoside lipid A (GLA). Freeze-thawing of the liquid 
vaccine caused the adjuvants to aggregate and decreased its immunogenicity in mice. 
Immunogenicity of liquid vaccines also decreased when stored at 40 °C for 8 weeks, as measured 
by decreases in neutralizing antibody titers in vaccinated mice. Concomitant with efficacy losses 
at elevated temperatures, changes in DNI structure were detected by fluorescence spectroscopy 
and increased deamidation was observed by capillary isoelectric focusing (cIEF) after only 1 week 
of storage of the liquid formulation at 40 °C. In contrast, upon lyophilization, no additional 
deamidation after 4 weeks at 40 °C and no detectable changes in DNI structure or reduction in 
immunogenicity after 16 weeks at 40 °C was observed. Vaccines containing aluminum hydroxide 
and GLA elicited higher immune responses than vaccines adjuvanted with only aluminum 
hydroxide, with more mice responding to a single dose.
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1. Introduction
The recommended storage temperature range for vaccines is typically very narrow1 and 
exposure to temperatures either above or below the recommended storage window may be 
detrimental with respect to vaccine potency2. For example, 75–100% of vaccines are 
exposed to freezing temperatures during transport through the cold chain3, which may cause 
vaccine formulations to experience at least one freeze-thaw cycle. Freeze-thawing of 
vaccines has been shown to cause aggregation of aluminum salt adjuvant particles4,5,6, 
perturbations in protein antigen structure4,7, and/or losses in immunogenicity4,8.
In addition to experiencing inadvertent freeze-thawing, vaccines may also be exposed to 
elevated temperatures causing protein antigens to experience physical9,10,11,12 or 
chemical13,14 degradation, resulting in a loss in vaccine potency11,15. To study the thermal 
sensitivity of vaccines, accelerated stability studies are typically conducted at temperatures 
significantly higher than the recommended storage temperatures. Accelerated stability 
studies are also commonly used as a predictor of long term stability and shelf life at optimal 
storage temperatures16.
Maintaining proper cold-chains is challenging, especially in developing countries. To 
alleviate this challenge, vaccines should be formulated to withstand a broad range of 
temperatures. Lyophilization is one strategy that can be applied to protect proteins and other 
therapeutic agents against temperature extremes, thereby relieving the constraints of the cold 
chain17. Formulation of live, attenuated measles vaccines in dry powders9 represents an 
example of this approach. Degradation in lyophilized formulations is inhibited in part 
because of the low water content and high viscosities (>1015 centipoise) found in glassy 
lyophilized formulations17.
Many vaccines require administration of multiple doses to confer adequate protection. 
Especially in developing countries, this requirement is problematic, and often patients do not 
complete multidose regimens18, 19. Presumably, better patient compliance would be 
obtained if vaccines required fewer doses. Adjuvants are often added to vaccines to increase 
vaccine potency, and offer the potential to decrease the required number of vaccine doses20. 
Aluminum salts, and aluminum hydroxide combined with monophosphoryl lipid A (MPL) 
have been approved for use as adjuvants in FDA-approved vaccines21. However, no FDA-
approved vaccines that contain adjuvants currently are marketed in lyophilized 
formulations22, in part because of the loss of vaccine efficacy that may occur during the 
requisite freezing step in the lyophilization process. Recent work has shown that by 
controlling the kinetics of freezing and glass formation through judicious choice of 
formulation and process conditions, highly stable, efficacious lyophilized vaccines 
containing aluminum salt adjuvants may be produced23, 24, 25,15.
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Aluminum salt adjuvants are known to stimulate primarily a humoral response. To produce 
a more robust cellular immune response to a vaccine, other adjuvants typically must be 
added26. One such co-adjuvant is monophosphoryl lipid A (MPL), a non-toxic derivative of 
lipopolysaccharide (LPS) that can act as a toll-like receptor-4 agonist26. Glycopyranoside 
lipid A (GLA) is a synthetic version of MPL that is more homogenous and active than 
MPL26. To date, there are no reports of commercial lyophilized vaccine formulations that 
combine both an aluminum hydroxide adjuvant and a cellular immunity stimulant such as 
GLA.
To examine the possibility of creating stable lyophilized vaccines containing both aluminum 
hydroxide and GLA, the anthrax vaccine candidate, Dominant Negative Inhibitor (DNI), 
was used as a model recombinant protein antigen. During Bacillus anthracis infection, 
bacteria secrete protective antigen (PA), lethal factor (LF) and edema factor (EF)27. PA 
forms complexes on the surface of host cells with LF (a zinc protease) and EF (an adenylate 
cyclase), giving rise to lethal toxin (LT) and edema toxin (ET), respectively. LT exerts its 
cytotoxic effects by interrupting mitogen-activated protein kinase kinase signaling, while ET 
influences intracellular cAMP levels. DNI is a recombinant version of PA (rPA) that 
contains the two point mutations: K397D and D425K. These mutations do not affect 
heptemerization or subunit binding, but do impair translocation of EF and LF into the 
cytoplasm of host cells28, 29. Previous studies have shown DNI to be an effective candidate 
vaccine antigen with respect to eliciting high PA antibody titers30, and the biophysical and 
immunological stability properties of the DNI antigen have been evaluated31. In addition, 
rPA is known to undergo chemical degradation via deamidation of specific Asn residues, 
including six labile sites out of the 68 total Asn residues in rPA33, which leads to loss of the 
antigen’s biological activity and immunogenicity32, 33, 34.
In this study we first tested the hypothesis that both heat and freeze-thaw stresses damage 
adjuvanted liquid vaccine formulations of DNI, decreasing their immunogenicity due to 
losses in protein structure and/or agglomeration of aluminum hydroxide adjuvant particles. 
Second, we evaluated the possibility that glassy-state, lyophilized formulations of DNI-
based vaccines are more robust against thermal stress, especially as reflected in slower rates 
of Asn deamidation, a known major chemical degradation pathway for rPA32, 33, 34. Finally, 
we tested the hypothesis that incorporation of the Toll-like receptor-4 (TLR4) agonist GLA 
together with microparticulate aluminum hydroxide in DNI vaccine formulations will confer 
additional potency, and that this additional functionality can also be protected against 
thermal stresses through lyophilization.
2. Materials and Methods
2.1 Materials
High purity α,α-trehalose dihydrate and sulfuric acid were purchased from Mallinckrodt 
Baker (Phillipsburg, NJ). Ammonium acetate, triethanolamine, and bovine serum albumin 
(BSA) were purchased from Sigma-Aldrich (St. Louis, MO). Two percent Alhydrogel® 
(aluminum hydroxide adjuvant, “alum”) was obtained from Accurate Chemicals and 
Scientific Corp (Westbury, NY). Lyophilized synthetic monophosphoryl lipid A 
(glycopyranoside Lipid A (GLA) adjuvant) was purchased from Avanti Polar Lipids, Inc. 
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(Alabaster, AL). Three mL 13 mm glass lyophilization vials, caps and seals were from West 
Pharmaceutical Services (Lititz, PA). Concentrated 10× phosphate buffered saline (PBS), 
and Tween 20 were from Fischer Scientific (Fair Lawn, NJ). Water for injection was 
purchased from Baxter Healthcare Corporation (Deerfield, IL). Peroxidase-conjugated 
affinipure donkey anti-mouse IgG (H+L) was from Jackson ImmunoResearch Laboratories, 
Inc. (West Grove, PA). 3,3’,5,5’tetramentylbenzidine (Ultra TMB) was from Thermo 
Scientific (Rockford, IL).
2.2 Vaccine formulation
Dominant negative inhibitor (DNI) protein manufactured by Baxter Pharmaceutical 
Solutions LLC (Bloomington, IN) was received as a lyophilized formulation containing 25 
mg DNI, 113 mg mannitol, 33 mg sucrose, and 2.4 mg dibasic phosphate. Lyophilized DNI 
was reconstituted in 3 mL of filtered DI water and dialyzed overnight with three buffer 
exchanges in a 10 mM ammonium acetate buffer pH 7 using 3,500 MWCO Slide-A-Lyzer 
dialysis cassettes from Thermo Scientific (Rockford, IL).
All vaccines were formulated to contain 10 mM ammonium acetate pH 7 with 0.2 mg/mL 
DNI and 0.5 mg/mL aluminum as Al(OH)3 (Alhydrogel). For isotonicity, 9.5 w/v% 
trehalose was added. In addition to aluminum hydroxide, 0.05 mg/mL GLA was added as a 
second adjuvant to half of the vaccine formulations. GLA was prepared at 1 mg/mL by 
suspending lyophilized GLA in a 0.5% triethanolamine pH 7 solution using probe 
sonication35. To create the vaccine formulations containing GLA, suspended GLA was 
added to Alhydrogel suspensions, vortexed for 5 seconds and then rotated end over end for 
30 minutes at 4 °C. 0.2 mg/mL DNI protein antigen was added to buffered adjuvant 
solutions and rotated end over end for 30 minutes to allow protein to adsorb completely to 
adjuvant particles.
2.3 Protein adsorption
Protein adsorption was measured by mass balance after centrifuging the vaccine formulation 
at 9,000×g for 4 min at 4 °C to remove particles and adsorbed protein, and measuring the 
unbound protein concentration in the supernatant through use of the Bradford assay. A 
standard curve was created using known concentrations of DNI. The amount of protein 
adsorbed to adjuvant was calculated by subtracting the amount of unbound protein from the 
known amount of protein in the vaccine.
2.4 Lyophilization
Vaccine formulations were lyophilized with 1 mL of formulation per vial. Lyophilizer 
shelves were pre-cooled to −10 °C (FTS Systems Lyophilizer, Warminster, PA) and vials 
were placed on the shelves. Vaccine formulations were surrounded by vials filled with DI 
water to minimize radiative heat transfer effects for vials near the edge of the lyophilizer 
shelves. The shelf temperature was decreased at a rate of 0.5 °C/min to −40 °C and then held 
at −40 °C for 1 hour to allow the samples to freeze completely. Primary drying was initiated 
by decreasing the chamber pressure to 60 mTorr and increasing the shelf temperature to −20 
°C at a rate of 2 °C/min. Samples were held at −20 °C for 20 hours. Secondary drying was 
conducted by increasing the shelf temperature to 0 °C at a rate of 0.2 °C/min followed by an 
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increase to 30 °C at a rate of 0.5 °C/min and holding the shelf temperature at 30 °C for 5 
hours. After drying, the shelf temperature was returned to 25 °C and the chamber was back-
filled with nitrogen until atmospheric pressure was reached. Chlorobutyl rubber stoppers 
were inserted into vials under a nitrogen atmosphere. Vials were sealed with aluminum caps, 
and then were stored at −80 °C. Lyophilized vaccines were stored at this low temperature to 
minimize molecular mobility and any resulting degradation in the formulations prior to their 
analysis or their use in accelerated stability studies.
2.5 Freeze-thaw study
Freeze-thaw stability was examined for liquid vaccine formulations. Formulations were 
cycled between −20 °C and 4 °C, leaving formulations at each temperature for one day to 
permit complete freezing or thawing. Vaccines experienced 0, 1, or 5 freeze-thaw cycles.
2.6 Elevated temperature incubation study
To test the stability of vaccines at elevated temperatures, liquid and lyophilized vaccines 
were stored at 4, 40 or 70 °C for 0, 1, 2, 4, 8, or 16 weeks. Time 0 lyophilized vaccines refer 
to vaccines reconstituted and used immediately after removal from storage at −80 °C.
2.7 Particle size analysis
Particle size distributions from 0.04–2,000 µm were measured using laser diffraction particle 
size analysis (LS 230, Beckman Coulter, Miami, FL). Initial liquid, and reconstituted 
lyophilized placebo vaccine formulations with and without GLA were measured. For each 
run, laser diffraction intensities were recorded three times for 90-sec each and averaged. 
Triplicate samples of each formulation were analyzed.
Particles in the size range of 2–2,000 µm were measured and counted by microflow image 
analysis (FlowCAM®, Fluid Imaging Technologies, Yarmouth, ME). Particle levels in the 
initial liquid formulations and in reconstituted formulations of lyophilized vaccines that had 
been incubated at 40 °C were measured in triplicate. 0.2 mL of samples diluted 10 times 
were run with a 100-µm flow cell using a 10× objective and collimator. Dark and light 
settings of 15 and 16 were used, respectively. For freeze-thaw studies, triplicate 1 mL of 
vaccine formulation diluted 100 times were analyzed with a 300-µm flow cell with a 4× 
objective. Dark and light settings of 20 were used.
2.8 Differential interference contrast microscopy
A Zeiss Axiovert 200M widefield microscope was used to take differential interference 
contrast images of vaccine formulations after 0, 1, or 5 freeze-thaw cycles. A 20× objective 
was used.
2.9 Differential scanning calorimetry (DSC)
Onset glass transition temperatures of placebo lyophilized formulations were obtained using 
differential scanning calorimetry (Diamond DSC, Perkin Elmer, Waltham, MA). Triplicate 
samples were prepared inside an aluminum pan under dry nitrogen. The temperatures in the 
pans were cycled twice between 25 °C and 150 °C at a scan rate of 10 °C/min. The second 
heating scan was used to determine the onset glass transition temperature.
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Intrinsic tryptophan fluorescence was measured by adding seven hundred µL of vaccine 
formulations from the freeze-thaw and incubation studies to 2×10 mm pathlength quartz 
cuvettes. The vaccine formulations were left in the cuvettes overnight at 4 °C to allow 
settling so that intrinsic fluorescence measurements could be performed in a fluorometer 
(Photon Technology International, Birmingham, NJ). For all vaccines, an excitation 
wavelength of 295 nm was used for fluorescence measurements, and the emission spectra 
were collected from 305–410 nm in 1 nm increments while the temperature was ramped 
from 10–70 °C in 2.5 °C increments. An equilibration time of 1 min was used at each 
temperature. Slit widths were set at 3 nm for excitation and emission. The intrinsic 
fluorescence peak positions as a function of temperature were calculated by a mean spectral 
center of mass method using in-house data analysis software (Middaugh Suite).
Extrinsic SYPRO orange fluorescence was measured by adding eighty nine µL of each 
vaccine formulation and one µL of 350× SYPRO Orange dye (Molecular Probes, Inc., 
Eugene, OR) to PCR tubes. PCR tubes were transferred to a Stratagene RT-PCR instrument 
(Agilent Technologies, Inc., Santa Clara, CA) and SYPRO Orange fluorescence was 
measured at 610 nm upon excitation at 492 nm while the temperature was ramped from 25 
to 70 °C in 1 °C intervals. An equilibrium time of 90 s was used at each temperature. The 
fluorescence intensity was normalized using a maxima-minima method using Microsoft 
Excel where the results are generated by fitting the data equal to one at the maxima and to 
zero at the minima.
All intrinsic and extrinsic fluorescence experiments were performed in duplicate and the 
signals of the samples were corrected for their respective blanks. The transition temperatures 
(Tm) were calculated using the second-order derivative of the peak position (intrinsic 
fluorescence) or SYPRO orange fluorescence intensity (extrinsic fluorescence) versus 
temperature data. Only the major transition (Tm) was analyzed for vaccine formulations, 
which showed more than one transition. Due to some irreversibility, these values are not 
thermodynamic Tm’s, but should be referred to as apparent Tm’s and used in a comparative 
manner only.
2.11 Deamidation study
Vaccine formulations subjected to freezing and thawing, and high temperature incubation 
were tested for changes in charge heterogeneity profiles, presumably due to Asn 
deamidation. Each formulation contained 1 mg/mL DNI protein in 10 mM ammonium 
acetate pH 7 with 9.5 w/v% trehalose. Formulations contained either 0 or 0.5 mg/mL 
aluminum as Al(OH)3 from Alhydrogel®. Liquid vaccine formulations from the freeze-thaw 
study were frozen and thawed in the presence of aluminum hydroxide adjuvant. Vaccine 
formulations for the thermal incubation study were in liquid or lyophilized forms during 
incubation at 40 °C with or without aluminum hydroxide adjuvant.
Analysis of charge heterogeneity profiles of DNI protein formulated with aluminum 
adjuvant required the DNI protein to be desorbed from aluminum hydroxide particles. The 
adjuvant-DNI complexes first were pelleted by centrifugation at 10,000×g for 3 minutes 
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(Sorvall Centrifuge, Thermo Scientific). The supernatant was removed and assayed for 
protein content by UV-visible absorption spectroscopy to confirm the absence of unbound 
protein. The pellet was resuspended in 1 mL of desorption media (10 mM ammonium 
acetate, 1 M phosphate and 5 M guanidine hydrochloride, pH 7.0). The resulting suspension 
was incubated at room temperature for 3 hours, followed by centrifugation at 10,000×g for 3 
min. The supernatant was collected and assayed for DNI content. These steps were repeated 
2 more times. The percent desorption was calculated by dividing the total content of protein 
in the collected supernatant by the initial amount of protein initially bound to the aluminum 
hydroxide particles. The supernatants were combined and buffer exchanged into 10 mM 
ammonium acetate, pH 7.0 using Amicon centrifugation filters (10 kDa MWCO). The 
protein content was again determined by UV-visible absorption spectroscopy to measure the 
final protein concentration prior to cIEF analysis.
To characterize changes in the distribution of DNI charge variants, which presumably result 
from asparagine deamidation events known to occur with recombinant PA32, 33, 34, cIEF 
experiments were performed on an iCE280 instrument from Protein-Simple (Toronto, 
Canada). All experiments were performed with duplicate samples at 4 °C using a 
temperature-controlled auto-sampler, with each sample measured in triplicate. Samples of 
DNI protein (final concentration 0.1 mg/ml) were mixed with Pharmalyte® 3.0–10.0 (final 
concentration of 4%, obtained from GE Healthcare), acidic and basic pI markers of 4.65 and 
8.18 (Protein-Simple, Canada), and methyl cellulose (final concentration of 0.35%, Protein-
Simple, Canada). In addition, 6M urea was added since it was found to provide better 
separation of the rPA charge variants. The optimized separation conditions included pre-
focusing at 1500V for 1 minute followed by 8 minutes of focusing at 3000V. Quantification 
of charge variants was performed using Chrom Perfect® software. The total number of 
deamidated residues per protein molecule was calculated by (1) determining the fraction of 
the total area for each cIEF peak, (2) multiplying each peak by the presumed number of 
deamidated Asn residues represented by each of the peaks, and (3) summing the obtained 
values for each peak in the cIEF electropherogram profile to determine the total number of 
deamidation events, as described in detail elsewhere36 using an analogous IEF gel system.
2.12 Vaccine immunogenicity
Murine studies were conducted under the University of Colorado at Boulder Institutional 
Animal Care and Use Committee (IACUC) protocol #1209.02. Female BALB/c mice 5–6 
weeks old from Taconic (Hudson, NY) were allowed to acclimate at least one week before 
use. Ten mice were in each group. Blood samples were collected from the mice under 
isofluorane anesthesia on days 0, 14 and 28 through the retro orbital cavity. The collected 
serum was separated by centrifugation at 10,000 rpm for 14 minutes at 4 °C and stored at 
−80 °C until analysis. On days 0 and 14, mice were injected subcutaneously behind the neck 
with various formulations. To study the effects of freeze-thawing on the immunogenicity of 
DNI vaccines, formulations in the presence or absence of GLA were subjected to 1 or 5 
freeze thaw cycles prior to administration to mice. To study the effects of incubation of DNI 
vaccine formulations at elevated temperatures, mice were injected with liquid vaccine 
formulations as positive controls, placebo lyophilized formulations as negative controls, 
liquid vaccine formulations that had been stored for 8 weeks at 40 °C, and lyophilized 
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vaccine formulations that had been incubated at 40 °C for 0, 1, 4, 8 and 16 weeks prior to 
reconstitution.
2.13 Total antibody enzyme linked immunosorbent assay (ELISA)
Nunc MaxiSorb 96 well plates (Thermo Fischer Scientific, Rochester, NY) were coated with 
50 µL/well of 1µg/mL DNI diluted in PBS and incubated at 2–8 °C overnight. Plates were 
washed 3 times with PBS containing 0.05% Tween 20. Plates were blocked with 300 µL/
well of PBS with 1% BSA, incubated at room temperature for 2 h, and washed again. Serum 
was initially diluted in PBS with 1% BSA, 0.05% Tween 20. 50-fold dilutions were used for 
serum collected on days 0 and 14, and 750-fold or 250-fold dilutions were used for serum 
collected on Day 28 for mice injected with or without GLA, respectively. A series of in-
plate 2-fold dilutions were made for each sample. Plates were incubated for 1.5 h at room 
temperature and washed. Forty µL of HRP-conjugated donkey anti-mouse antibody diluted 
10,000 times was added to each well and incubated for 1.5 h at room temperature with 
shaking, followed by washing. 40 µL TMB was added to each well and incubated for 15 
min, followed by quenching with 40 µL of 2N sulfuric acid. Plates were measured at 450 nm 
on a Molecular Devices Kinetic Microplate Reader (Sunnyvale, CA). Each serum sample 
was analyzed in triplicate.
To determine titers, average OD 450 values as a function of dilution were fit to a 4-
parameter logistic equation using SigmaPlot software (Systat Software Inc., San Jose, CA). 
The constraints 0 < min < 0.15 and max < 3.3 were used. The cutoff value was calculated 
individually for each mouse as five times the value given on day 0 at a dilution of 100. To 
evaluate statistically significant differences between groups, a t-test was used for normally 
distributed groups and a Mann-Whitney Rank Sum Test on non-normally distributed groups.
2.14 Neutralizing antibodies
J774 cells grown in DMEM plus 10% FBS were seeded (5×103 per well) in white 96 well 
cell culture plates and incubated at 37 °C overnight. Serum samples were mixed at a 1:100 
dilution into media containing lethal toxin (300 ng/mL, 1:1 PA:LF), then diluted two-fold in 
a separate dilution plate into toxin-containing media, down to a 1:12,800 dilution. The 
media was removed from the cell wells, and toxin-serum mixtures were transferred into 
them and incubated for 24 h at 37 °C. Some cells received media or toxin-containing media 
only, and served as live and dead controls, respectively. Cell viability was assessed using 
Cell Titer Glo (Promega, Madison, WI) and a Spectramax L Luminometer (Molecular 
Devices, Sunnyvale, CA). Neutralizing titers were defined as the inverse titer that protected 
at least 50% of the cells from lethal toxin.
3. Results
3.1 Freeze thaw studies – Vaccine characterization
Initially, all liquid vaccine formulations appeared identical based on differential interference 
contrast microscopy regardless of adjuvant present (Figure 1). After one freeze-thaw cycle 
loose clumping of adjuvant particles was observed. After five freeze-thaw cycles, large 
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particles (>10 µm) were seen in all formulations, irrespective of the presence or absence of 
GLA.
The concentration of particles of size greater than 5 microns in each formulation was 
measured using a FlowCAM microflow imaging instrument (Figure 2). All vaccine 
formulations started with particles of similar mean particle diameters (~7–10 µm) and 
concentrations (~1 million particles/mL). After one freeze-thaw cycle, a small increase in 
mean particle size (to ~12 µm) was observed. After five freeze-thaw cycles, the mean 
particle size in each of the formulations was approximately 20 µm. Concomitant with the 
formation of larger particles, there were decreases in the number of smaller particles found 
in the formulations. Both formulations had particle concentrations that were of the same 
order of magnitude throughout the freeze-thaw study.
DNI was found to be adsorbed completely to adjuvant in all vaccine formulations tested, 
both initially and after 1 or 5 freeze-thaw cycles (data not shown). After formulations 
containing DNI adsorbed to aluminum hydroxide particles were pelleted by centrifugation 
and resuspended in PBS for 1 hour at 37 °C, ~20% of the DNI desorbed.
3.2 Effect of freeze-thawing on antigen structure
Intrinsic tryptophan and extrinsic SYPRO Orange fluorescence studies were conducted to 
examine protein structure after 0, 1, and 5 freeze-thaw cycles. DNI in all formulations, 
regardless of the number of freeze-thaw cycles, or the presence of adjuvants, exhibited a 
cooperative thermal transition at approximately 45 °C suggesting negligible effect of freeze 
thaw stress on conformational/structural stability of DNI. In addition, no increase in 
deamidation events was detected by cIEF after 1 or 5 freeze thaw cycles in vaccine 
formulations (data not shown).
3.3 Freeze thaw studies - Immunogenicity
Liquid vaccine formulations were subjected to 0, 1 or 5 freeze-thaw cycles and injected into 
mice. All mice responded with anti-DNI antibodies after two injections of the vaccine 
regardless of the number of freeze-thaw cycles, but more non-responders were seen after 
one injection of the Alum+DNI formulation that had been subjected to five freeze-thaw 
cycles. After one injection, a significant decrease in titer was seen for both the Alum+DNI 
and Alum+GLA+DNI vaccines exposed to 5 freeze-thaw cycles when compared to vaccines 
not exposed to freezing and thawing (p=0.007 and p=0.011, respectively) (Figure 3A). 
Neutralizing titers in sera collected after the second immunization elicited by the various 
formulations were not significantly reduced as compared to the initial vaccine for any of the 
formulations (Figure 3B). Neutralizing titers were not measured after the first immunization.
3.4 Elevated temperature studies – Vaccine characterization
To ensure that lyophilized vaccines were stored in a glassy state, glass transition 
temperatures were measured in lyophilized placebo formulations (without protein). The 
glass transition temperature for placebo vaccine formulations without and with GLA were 
115.5 ± 1.6 °C and 117.3 ± 3.8 °C, respectively. The glass transition temperatures of the 
formulations were very similar to that of pure trehalose, 110–120 °C37, showing that the 
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water content of the formulations was minimal. Previous work with similar formulations and 
lyophilization cycles suggests that the water content was below 1%15. If water were present 
in the formulation, the glass transition temperature would be drastically reduced because 
water acts as a potent plasticizer37. Since the glass transition temperatures were significantly 
higher than the storage temperatures tested in this study (4, 40 and 70 °C), the lyophilized 
vaccine formulations remained in a glassy state during storage. Due to the associated large 
increases in molecular mobility, degradation rates typically increase dramatically when 
lyophilized formulations are stored above their glass transition temperatures.
Previous work showed that formulations containing aluminum salt adjuvants can be 
lyophilized and reconstituted without significant changes to the initial liquid particle size 
distribution, provided that sufficient amounts of trehalose are used in combination with rapid 
cooling methods before lyophilization23,15. Particle size distributions were determined for 
initial liquid and reconstituted lyophilized placebo formulations with and without GLA 
(Figure 4). Vaccine formulations without GLA had similar particle size distributions before 
and after lyophilization and reconstitution, whereas vaccine formulations containing GLA 
exhibited slight increases in particle size after lyophilization and reconstitution.
For each lyophilized and reconstituted formulation, a significant increase compared to the 
initial liquid formulations in the number of particles greater than 2 microns in size was 
observed by FlowCAM analysis (Figure 5). A greater number of particles were detected in 
formulations containing GLA, and even more particles were observed when DNI was added 
to the formulation. After the initial increase in particles following lyophilization, no further 
increase in particle counts could be detected after incubation at 40 °C for up to 16 weeks.
DNI adsorption to adjuvant particles was measured in liquid formulations prior to 
lyophilization, in reconstituted lyophilized formulations, and in lyophilized and reconstituted 
vaccine formulations that had been incubated at 40 °C for up to 16 weeks. Essentially 
complete (90–100%) adsorption of the DNI protein to aluminum hydroxide adjuvant was 
observed for all conditions tested (data not shown). When aluminum hydroxide particles 
with adsorbed DNI were collected by centrifugation, resuspended in PBS and incubated at 
37 °C for one hour, only 70% of DNI remained adsorbed, suggesting that DNI may at least 
partially desorb in vivo after injection.
3.5 Effect of elevated temperatures on antigen structure
Prior to storage at elevated temperatures, cooperative thermal transitions were observed in 
all DNI samples when analyzed by either intrinsic tryptophan or extrinsic SYPRO Orange 
fluorescence spectroscopy. In all of the formulations, the main structural transition for DNI 
occurred at a temperature of ~45 °C. Intrinsic fluorescence spectra of DNI adsorbed to 
adjuvant in liquid suspensions showed ~2 nm red-shift in peak positions compared to those 
for DNI in solution, potentially indicating conformational perturbation in DNI upon 
adsorption to the adjuvant surface (data not shown). Examples of thermal scans of intrinsic 
and extrinsic fluorescence of DNI samples used to calculate thermal melting temperature 
(Tm) values are shown in Figure 6.
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After storage at 4 °C for 1, 2, 4, 8, and 16 weeks, analysis of the protein’s conformational 
stability showed thermal transitions at ~45 °C for all DNI samples (Figure 6 and Table 1). 
However, when liquid samples (with adjuvant) were stored at 40 or 70 °C, no thermal 
transitions were observed by fluorescence analysis, suggesting that unfolding of the protein 
had occurred during storage at these elevated temperatures. In liquid samples containing 
DNI (without adjuvant), clear thermal transitions were observed after incubation at 40 °C for 
up to 4 weeks, a weak transition was detected after 8 weeks of incubation, and no transitions 
could be detected after 16 weeks (Table 1). These results demonstrate the loss of structural 
integrity of DNI during storage in solution at 40 °C over several months. No structural 
transitions were detected for liquid DNI samples (with or without adjuvant) that had been 
stored at 70 °C for any length of time. In contrast, after storage at any of the tested 
temperatures for a period of up to 16 weeks, lyophilized vaccine formulations displayed 
cooperative thermal transitions, indicating improved storage stability, as measured by 
conformational stability analysis, of the DNI in the lyophilized dosage form compared to the 
liquid formulations.
Deamidation of the DNI protein was significantly slowed in the lyophilized state compared 
to the liquid state at elevated temperatures as shown in Figure 7 (with representative 
electropherograms shown in Supplemental Figure S1). Both liquid and lyophilized 
formulations showed no increase in new DNI deamidation events during storage at 4 °C for 
up to 4 weeks. However, when liquid formulations were stored at 40 °C, increased charge 
heterogeneity with additional acidic peaks, consistent with the known Asn deamidation 
events in rPA protein32,33,34, was detected by cIEF analysis after 1 week of storage. In 
contrast, as shown in Figure 7, no increase in deamidation events was detected in 
lyophilized formulations (with or without aluminum adjuvant) for up to 4 weeks at 40 °C. 
Moreover, liquid formulations containing aluminum hydroxide adjuvant showed 
significantly faster deamidation than DNI formulations without adjuvant at 40 °C over 1–2 
weeks. Interestingly, for liquid formulations stored at either 4°C or 40 °C for 4 weeks, the 
charged isoforms of DNI displayed a reduced total area by cIEF analysis in the presence vs. 
the absence of aluminum adjuvant (Supplemental Figure S1B). Although the nature of this 
effect requires more study (e.g., it may reflect more extensive deamidation of the multiple 
Asn residues, or other structural alterations, in the DNI protein), it was not observed with 
lyophilized DNI formulations further supporting the stabilizing effects of lyophilization. In 
summary, we conclude that lyophilized DNI formulations were highly resistant to 
deamidation (as measured by formation of new acidic peaks by cIEF) compared to the 
corresponding liquid formulations.
3.6 Elevated temperature studies – Immunogenicity
The immunogenicity of the vaccine formulations were evaluated based on serum anti-DNI 
IgG titers as well as serum LT-neutralizing activity in a mouse macrophage cytotoxicity 
assay. Immunization of mice with liquid vaccines that had been stored at 40 °C resulted in 
the production of anti-DNI antibodies, but very few mice responded with neutralizing titers 
(Figure 8). Although the protein antigen in the liquid vaccine stored for 8 weeks at 40 °C 
was able to produce antibodies that recognize native DNI by ELISA, these antibodies were 
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not effective at neutralizing LT, which is consistent with the structural data indicating the 
loss of antigen physicochemical structure when stored at 40 °C.
Lyophilization did not acutely affect the immunogenicity of the vaccines. Liquid vaccines 
and vaccines reconstituted immediately after lyophilization produced equivalent immune 
responses, both in the presence and absence of GLA (p=0.307 and p=0.775, respectively). 
However, unlike the liquid formulations, lyophilized formulations stored at 40 °C up to 16 
weeks with (p=0.793) and without GLA (p=0.347) were as effective as unstressed liquid 
vaccine formulations at eliciting DNI antibodies and LT neutralizing activity. Moreover, 
after two injections, the liquid vaccine formulation containing GLA produced significantly 
higher anti-DNI serum IgG antibody titers and toxin-neutralizing activities than the 
formulations without GLA (p≤0.02). In addition, a single injection of vaccine formulations 
containing GLA resulted in significant levels of DNI-specific antibodies, whereas 
formulation without GLA often typically required two injections in order to elicit a 
significant antigen-specific response.
4. Discussion
Since all lyophilized vaccines experience freezing once during the lyophilization process 
and a large fraction of vaccines experience freezing temperatures at least once during 
passage through the cold chain, freeze-thaw studies were conducted. Vaccine formulations 
were first exposed to one freeze-thaw cycle to mimic damage that might be caused due to 
freezing during the lyophilization process. The structure of DNI within these formulations 
appeared to be unaffected by freeze-thawing, or by lyophilization and reconstitution based 
on structural (Tm values for DNI determined from fluorescence scanning) and chemical 
(DNI charge heterogeneity profile by cIEF to monitor deamidation) integrity of the protein. 
Freezing and thawing the vaccine formulations one time caused an increase in the number of 
particles as well as an increase in larger sized particles. Since the rate of freezing used in the 
freeze-thaw study was different from the lyophilization cycle, the increase in particle 
formation was different for each study. After vaccines were frozen and thawed once, their 
immunogenicities were similar to that of the initial liquid vaccine. Additionally, lyophilized 
and reconstituted versions of the same vaccine formulation generated immune responses 
similar to those of the initial liquid form. These results demonstrate that the freezing stage of 
lyophilization should not cause damage to the vaccine.
Vaccine formulations were frozen and thawed five times to mimic more extensive damage 
that could happen as a result of thermal excursions during shipping and storage. After five 
freeze-thaw cycles, vaccine formulations exhibited no physicochemical alterations to protein 
antigen as measured by protein melting temperatures and charge heterogeneity profiles. 
Larger particles were formed at the expense of smaller particles with more freeze-thaw 
cycles. Although no differences in immunogenicity (compared to responses resulting from 
administration of comparable vaccine formulations that were not subjected to freeze-
thawing) were detected after two injections, reduced anti-DNI antibody titers were observed 
after administration of single doses of both the vaccine formulations containing alum and 
DNI, and formulations containing alum, GLA and DNI. After five freeze-thaw cycles, the 
fraction of mice responding with anti-DNI antibodies to the alum-containing DNI vaccine 
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after a single injection decreased from 80% to 20%, although 100% responded after two 
injections. The exact cause of the reduced immune response to the first dose is still 
debatable, although it may be associated with changes in aluminum hydroxide particle size 
resulting from the multiple freeze-thaw cycles.
Liquid vaccine formulations lost potency following exposure to higher temperatures. The 
protein structure in liquid formulations was perturbed after 1 week of storage at 40 °C. In 
contrast, DNI structure was preserved in lyophilized vaccine formulations, even after storage 
at 70 °C for 16 weeks. Additionally, in separate studies at 40 °C over 4 weeks, 
lyophilization was shown to prevent deamidation of the DNI protein, even in the presence of 
aluminum hydroxide particles. Previous studies have shown that protein antigens such as 
rPA and Botulinum neurotoxin deamidate faster in the presence of an aluminum salt 
adjuvant presumably due to higher surface pH of the adjuvant13, 34. The immunogenicity of 
liquid vaccines was compromised by 8 weeks of storage at 40 °C, whereas the 
immunogenicity of lyophilized vaccines was retained after storage at 40 °C for 16 weeks.
To administer the vaccine formulations in as few doses as possible, reducing transportation 
needs and cost while increasing patient compliance, GLA could be added to vaccine 
formulations already containing aluminum hydroxide. The immunogenicity of vaccine 
formulations containing GLA was higher after one injection than formulations without 
GLA. The response after one injection with GLA was almost as high as two injections 
without GLA, demonstrating the ability of GLA to increase the immune response and reduce 
the required number of doses. Also, a higher percentage of mice responded after one 
injection to vaccines containing GLA. Similar results were seen when the related MPL 
adjuvant was added to human Papillomavirus vaccines38, 39.
5. Conclusions
Damage can be caused by both elevated and freezing temperatures in liquid vaccine 
formulations. Freeze-thaw cycles were found to be detrimental to a DNI vaccine’s 
immunogenicity and aluminum hydroxide particles. Lyophilized DNI formulations showed 
much better physicochemical stability than the liquid formulations upon incubation for up to 
16 weeks at 4, 40 and 70 °C based on fluorescence structural studies and cIEF deamidation 
measurements. To complement the structural studies, lyophilized vaccines stored at 40 °C 
did not lose immunogenicity for storage up to 16 weeks whereas liquid vaccines lost 
immunogenicity prior to 8 weeks. The immunogenicity of vaccines containing GLA was 
much higher than vaccines that contained only aluminum hydroxide adjuvant. After only 
one injection, vaccines that contained GLA produced a higher percentage of mice that 
responded with anti-DNI and neutralizing antibodies.
In lyophilized vaccine formulations, variations in temperature during transport are less 
detrimental to vaccine potency. In the lyophilized state minimal water is present, avoiding 
any potential damage by freeze-thaw events. Lyophilized vaccines also permit longer 
storage at recommended temperatures and can remain immunogenic for short excursions to 
elevated temperatures if breaks in the cold chain occur.
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Aluminum hydroxide adjuvant particles aggregated during freezing and thawing as seen by 
differential interference contrast microscopy images after 0, 1, and 5 freeze-thaw cycles. 
More particle aggregation was observed with increasing the number of freeze-thaw cycles.
Hassett et al. Page 17























Particle concentrations of formulations after 0, 1, 3, and 5 freeze-thaw cycles. With 
increasing numbers of freeze-thaw cycles, a decrease in 5–10 µm particles was detected and 
an increase in larger particles was seen. Particle size ranges are 5–10 µm (black), 10–20 µm 
(dark gray), 20–30 µm (light gray), 30+ µm (white).
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Total anti-DNI antibody titers (A) and neutralizing antibody titers (B) after one vaccine 
injection (white circles) and after two vaccine injections (gray circles) for liquid vaccine 
after 0, 1, and 5 freeze-thaw cycles. Reduced immunogenicity was detected with 5 freeze-
thaw cycles after one injection. Toxin-neutralizing endpoint titers were only determined 
using serum samples collected after the second immunization.
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Particle size distributions of placebo vaccine (gray) and placebo vaccine with GLA (black) 
before (solid line) and after lyophilization and reconstitution (dashed line). Initial liquid 
particle size distributions were very similar for both formulations. After lyophilization and 
reconstitution, only a slight increase in particle size distribution was seen in the formulation 
containing GLA.
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Particle size and concentration for particles greater than 2 microns in liquid and 
reconstituted lyophilized vaccines formulations. Particles 2–5 µm (black), 5–10 µm (dark 
gray), 10–15 µm (light gray) and greater than 15 µm (white). An increase in particle number 
was seen when the formulations were lyophilized and reconstituted but no change was seen 
when the vaccine was incubated at 40 °C for up to 16 weeks.
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Examples of intrinsic Trp (top row) and extrinsic SYPRO Orange (bottom row) fluorescence 
thermal melting curves for DNI vaccine formulations after being stored at 4 °C (A), 40 °C 
(B), and 70°C (C) for 4 weeks. DNI samples were liquid formulation (black), liquid 
aluminum formulation (red), lyophilized aluminum formulation (blue), liquid aluminum 
formulation with GLA (purple) and lyophilized aluminum formulation with GLA (green). 
Lyophilized samples were reconstituted prior to analysis.
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Extent of DNI deamidation as measured by cIEF increased during storage at higher 
temperatures and in the presence of aluminum hydroxide adjuvant when stored as liquid 
formulations. Lyophilized DNI vaccines showed no increase in deamidation events during 
storage, even at higher temperatures. DNI samples include: liquid formulation at 4 °C 
(black) and 40 °C (blue), liquid aluminum formulation at 4 °C (red) and 40 °C (pink), 
lyophilized formulation at 40 °C (green), and lyophilized aluminum formulation at 40 °C 
(navy). Representative cIEF electropherograms are shown in Supplemental Figure S1. See 
methods section for calculation of deamidation events; duplicate samples were analyzed in 
triplicate (n=6) with error bars showing standard deviation values.
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Total anti-DNI antibody titers (A) and neutralizing antibody titers (B) after one vaccine 
injection (white circles) and after two vaccine injections (gray circles) for liquid and 
reconstituted lyophilized Alum (A), Alum+GLA(AG), Alum+DNI (AD) and Alum+GLA
+DNI (AGD) vaccines stored at 40 °C for 0–16 weeks. Lyophilized vaccines remain 
immunogenic even after storage at 40 °C for 16 weeks, where liquid vaccines showed a 
decrease in immunogenicity after 8 weeks of incubation.
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Table 1
DNI-containing vaccines incubated at 4, 40 or 70 °C for 0–16 weeks exhibiting fluorescent melting 
temperatures at 40–50 °C as measured by intrinsic and extrinsic SYPRO Orange methods (●) or only the 
intrinsic method (○). Sample without detectable transitions are denoted with (○) symbols indicating loss of 
structural integrity. Lyophilized vaccines maintained DNI thermal melting temperatures during incubation at 
the three temperatures, where liquid vaccines did not exhibit detectable melting temperatures when stored at 




4 °C 40 °C 70 °C
Liquid Unbound DNI
0 ●
1 ● ● ○
2 ● ● ○
4 ● ● ○
8 ● ○ ○
16 ● ○ ○
Liquid Alum+DNI
0 ●
1 ● ○ ○
2 ● ○ ○
4 ● ○ ○
8 ● ○ ○
16 ● ○ ○
Liquid Alum+GLA+DNI
0 ●
1 ● ○ ○
2 ● ○ ○
4 ● ○ ○
8 ● ○ ○
16 ● ○ ○
Lyophilized Alum+DNI
0 ●
1 ● ● ●
2 ● ● ●
4 ● ● ●
8 ● ● ●
16 ● ● ●
Lyophilized Alum+GLA+DNI
0 ●
1 ● ● ●
2 ● ● ●
4 ● ● ●
8 ● ● ●
16 ● ● ●
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